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ABSTRACT
Hematopoietic stem cell transplantation (HSCT) as a field of medicine has been subject to rapid development and
evolution since its inception. Traditionally, HSCT has been used for therapy of a diverse group of malignancies,
bonemarrow failure states, and inherited disorders. The rapid evolution of transplantation technology coupled with
the diverse outcomes associated with a heterogeneous group of patients has stymied the development of consensus
over objective programmatic indicators of quality, especially as they pertain to outcomes. In some regard, the lack
of consensus has caused transplant programs to respond to a more consumer-driven paradigm of evaluation. The
community of providers of transplantation therapies has responded by establishing standards for accreditation of
facilities and uniform presentation of programmatic data. Rapid acceptance of the need for meaningful quality
programs to address all aspects of the transplant facility has moved HSCT to the forefront of implementing
standards for medical practice. Because definition of optimal outcomes in HSCT is likely to remain elusive, it is
imperative that providers involved with HSCT continue to take a leadership role in defining program quality
through further research.
© 2005 American Society for Blood and Marrow Transplantation
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Hematopoietic stem cell transplantation (HSCT)
mbodies a ﬁeld of therapy directed toward treatment of
diverse group of malignant and nonmalignant diseases.
his ﬁeld is comparatively young in development, hav-
ng only recently moved from an experimental and ﬁnal
reatment in advanced leukemia to standard, often front-
ine therapy in several diseases. HSCT as a discipline
ontinues to rapidly evolve through translation of dis-
overies in the basic and clinical aspects of immunology,
ncology, and infectious diseases into the transplant
linic. The continuing evolution of clinical care and the
iverse group of patients and diseases treated with
SCT have contributed to disagreement as to how to
stablish measures of quality in transplant programs.
CCOUNTABILITY FOR QUALITY
Quality of health care remains a topic of intense
nterest at all levels of the health-care delivery system. g
B&MTeasurement of quality is no less important in HSCT
han in other areas of medicine and may even be more
mportant, for a host of reasons. These include the
ife-threatening nature of the diseases (and, occasion-
lly, the treatment), the opportunity for cure, the
ntensive resource utilization, and the involvement of
ealthy donors in HSCT. It is quite likely that results
f all transplant centers do not yield equivalent out-
omes [1]. Despite the acceptance of HSCT as the
tandard of care, meaningful measures of program
uality are still in development.
Providers involved with HSCT are not substan-
ially different from their colleagues in that they tend
o deﬁne quality in terms of the appropriateness of the
ervice provided and the skill with which it is deliv-
red, otherwise termed technical excellence [2]. With
ittle information available about technical excellence
n HSCT, other perspectives on quality—especially
hose of consumers—have been emphasized. As a
roup of providers, transplant services have been in-
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2reasingly sensitive to the preferences of consumers.
his trend is not unique to HSCT, and there is a
ecognition that the opinions of consumers, especially
atients, are important indicators of quality [3]. What
ay be unique is that the absence of objective and
obust technical measures associated with superior
utcomes renders the stem cell transplant community
usceptible to evaluation by more subjective measures.
Centers providing transplantation therapies are
ccountable to several groups who have a vested in-
erest in ensuring the best possible outcomes. We are
ccountable to the patient ﬁrst and foremost. Patients
ant and need to know that they are being treated at
transplant center that offers high-quality care. In
any situations, HSCT remains a therapy with sig-
iﬁcant risks but offers the potential for cure of oth-
rwise life-threatening illnesses. Patients rightfully
emand to be treated in the best facilities with the
atest technologies. However, the ramiﬁcations extend
eyond the opportunity for cure to more complex
ssues involving individualization of therapy to achieve
he best quality and length of life. This concern is
ummarized in a statement culled from the Work
roup on Consumer Health Information:
The cry for federal legislation to protect pa-
tients’ rights reﬂects a growing anxiety about
quality. Quality varies widely across health
plans and providers. Many procedures and
therapies are used too often, while others are
not used often enough. No institution or ofﬁce
is free from errors [4].
Physicians who refer patients for HSCT have a
een interest in selecting the highest-quality centers
or their patients. These physicians frequently have
nvested signiﬁcant effort in preparing patients for
ransplantation as part of an overall treatment plan.
oreover, treatment of the sorts of desperate condi-
ions addressed by HSCT leads to close physician-
atient relationships. Referring physicians therefore
xpect the centers they have selected to have outcomes
hat are at least comparable, if not superior, to those of
ther centers.
Payers have signiﬁcant interests in quality. To
epresent their transplant networks to employers as
uality providers, they must have a means of differen-
iating contracted facilities from others. Once con-
racted with an employer or plan, the payer has an
ngoing responsibility to ensure that the patients they
over have access to qualiﬁed providers. This respon-
ibility can be especially challenging to the payer be-
ause of the rapid evolution of treatment standards
nd the appropriate emphasis placed on clinical re-
earch in the ﬁeld. Additionally, we must realize that
here are ﬁnancial considerations for the payer. Un-
erpinning the concept of value inherent in contract- s
42ng for quality care is that quality is frequently asso-
iated with cost-effective therapy.
Purchasers (such as employers) of health-care ser-
ices have increasingly become involved in under-
tanding issues of quality in HSCT. Although it is a
omparatively rare occurrence that an employee or
ependent needs a transplantation, the rapidly evolv-
ng indications and high cost of the procedure can
reate challenges for the employer in understanding
nd purchasing transplantation beneﬁts.
Determinants of clinical quality have also become
mportant for government regulators such as the Food
nd Drug Administration (FDA). In its role of evalu-
ting the safety and efﬁcacy of new drugs and devices
n transplantation therapies, the FDA has had an in-
erest in understanding the effectiveness and predict-
bility of transplantation outcomes in speciﬁc situa-
ions. The rapid evolution of cellular therapeutics in
articular has increasingly blurred the lines among
egulatory issues, research issues, and the clinical
ractice of medicine. The FDA has responded with a
ational and comprehensive restructuring of the way
ells and tissues are collected, processed, and stored
5]. In the absence of reliable, predictable patient
utcomes for the transplantation of cells for tissue
epair and for hematologic and immunologic recon-
titution, determinants of clinical quality become im-
ortant in evaluating new technologies.
Finally, providers of HSCT therapies have an in-
erest in deﬁning the programmatic elements that lead
o clinical quality. Transplant programs are best po-
itioned to select, prioritize, and analyze indicators of
uality. Such activities are important so that key ele-
ents may be transported to other facilities to im-
rove outcomes, as well as for the internal beneﬁt they
arry. The measurement and improvement of quality
n HSCT programs ultimately requires the involve-
ent and leadership of those who deliver the services:
amely, transplant physicians and other health-care
roviders [6].
In the absence of metrics that clearly differentiate
ne center from another, each of these groups uses
arameters that they perceive as important or with
hich they are familiar to evaluate facilities. Parame-
ers such as those listed in Table 1 may or may not be
redictors of superior outcomes. Of these, the most
onsistently applied have been the credentialing crite-
ia used for inclusion in payer networks. Some of these
lements have greater validity than others in evaluat-
ng an HSCT program, but none has ever been for-
ally evaluated to determine its relationship to out-
ome or quality. Most centers now pay particular
ttention to the parameters required for acceptance
nto payer networks. The need to meet payer-deﬁned
ndicators for inclusion into such networks may have
lso facilitated the improvement of quality systems in
ome facilities [7].
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What Is Quality in a Transplant Program?
BThese perceptions by patients, payers, and refer-
ing physicians are not ideal substitutes for precise
easures of quality. To some degree, all 3 groups have
istorically depended on the HSCT center to ensure
uality outcomes and have focused on the more op-
rational aspects of the programs in their evaluations.
he increasing demands placed on programs to meet
he credentialing requirements of payers has caused
SCT programs to address quality-of-care issues to
emain competitive in the market.
UTCOME MEASURES
Improving clinical outcomes—speciﬁcally, survi-
al—after any form of therapy should ultimately be
he basis for gauging quality care. However, in the
etting of HSCT, this may be problematic. For exam-
le, a payer might ask for survival data for patients
ith acute myelogenous leukemia in ﬁrst remission to
e the basis of center quality. With the limited num-
er of HSCTs performed at each center for this type
f clinical indication, a valid statistical representation
f a quality measure based on this parameter is a gross
isrepresentation. The use of such a paradigm is
nﬂuenced by the payer’s experience in evaluating cen-
able 1. Perceptions of Quality According to Consumers of
ransplantation Services
Stakeholder Parameter Indicator
atient Facility reputation Referring physician
Case manager
Internet
Value-added
service
Out-of-pocket costs
Access
Communication/teaching
Spiritual/mental support
Support for caregivers
ayer Structural
indicators
Patient volume and
survival
Physician number and
training
Program age
Publications
Process indicators Quality-improvement
program
Accreditations: FACT,
AABB, JCAH
Operational
indicators
Communication
Patient satisfaction
Contract rates
Contract management
eferring
physician
Communication
Accessibility
Outcomes of referred
patients
ACT indicates Foundation for the Accreditation of Cellular Ther-
apy; JCAH, Joint Commission for the Accreditation of Health-
care Organizations; AABB, American Association of Blood
Banks.ers that perform solid-organ transplantations. 1
B&MTThe Scientiﬁc Registry of Transplant Recipients
SRTR; http://www.ustransplant.org) can provide fur-
her insight into this problem. SRTR supports the
ngoing evaluation of the scientiﬁc and clinical status
f solid-organ transplantation. SRTR contains rela-
ively detailed information about patients waiting for a
ransplantation, donor characteristics, and 200 000
rgan transplant recipients. The SRTR is adminis-
ered by the University Renal Research and Education
ssociation in collaboration with the University of
ichigan and is funded through the Health Resources
nd Services Administration. On the SRTR Web site,
ata by center and type of transplantation can be
ccessed. Information on crude and risk-adjusted graft
nd patient survival at 1 month, 1 year, and 3 years is
vailable online. Rates are also provided according to
peciﬁc patient characteristics (by sex, ABO blood
ype, and so on) or by center and can be compared
ith expected national outcomes.
For a variety of reasons, center-speciﬁc outcome
nalysis similar to SRTR may be problematic for eval-
ation of HSCT facilities. To illustrate this point,
igure 1 shows data aggregated from the International
one Marrow Transplant Registry (IBMTR). The sur-
ival rates based on all reported patients according to
ype of transplantation are shown: matched-sibling
ransplantations, unrelated donor transplantations,
nd autologous transplantations. The ﬁgure indicates
hat regardless of the type of transplantation, there is
pproximately a 40% to 50% rate of long-term dis-
ase-free survival.
Using this ﬁgure to benchmark a particular cen-
er’s survival data is limited by transplant center size
nd the clinical case mix. Figure 2 shows the 95%
onﬁdence intervals for samples drawn from a popu-
ation receiving a treatment that produces a 50% sur-
ival probability. To achieve an estimate with a 10%
argin of error, a center needs to perform 100 cases per
ear. Few centers achieve such volumes, and, according
o the IBMTR, themedian size of its reporting programs
s fewer than 30 patients per year (Figure 3). Survival
utcomes also vary according to disease, disease stage,
ype of graft, type of transplantation, disease indica-
ions, and outcome expectations, to name a few.
In organ transplantation, an organ may be trans-
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igure 1. Survival after hematopoietic stem cell transplantations,
996 to 2000.
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2lanted to address end-stage organ disease from a variety
f causes. Similarly, the same HSCT procedure may be
erformed for a variety of illnesses, such as multiple
yeloma, non-Hodgkin lymphoma, and acute myelog-
nous leukemia. Unlike organ transplantation, however,
he expected outcomes of therapy are dependent on the
isease. For example, the expected outcome for an au-
ologous stem cell transplantation for Hodgkin disease is
ure, whereas for multiple myeloma it is usually pallia-
ion, because virtually all patients relapse. Subgroups of
atients do quite well, such as those with early leukemia
nd aplastic anemia with sibling transplants, autologous
ransplants for Hodgkin disease in complete remission,
nd intermediate- and low-grade lymphomas. There are
ther subgroups in which success is not as predictable,
uch as the accelerated phase of chronic myelogenous
eukemia with matched sibling transplants and acute leu-
emia past ﬁrst complete remission. Unfortunately,
here are also groups that have generally poor outcomes,
uch as transplantations for advanced chemotherapy-
efractory diseases. Because of these factors, patients re-
eive varying preparative regimens and transplantation
trategies that lead to different causes of morbidity and
ortality after transplantation. With so many important
ariables potentially affecting outcomes, performing the
ppropriate stratiﬁcations and risk adjustments to exam-
ne whether a particular center meets the 50% 1-year
urvival rate is problematic.
An alternative approach would be to evaluate mul-
iyear cohort outcomes to fulﬁll the number require-
ents, provided that appropriate risk stratiﬁcations
re considered and assuming that the technology as-
ociated with transplantation has not drastically
hanged over the years. Again, the rapid evolution of
ransplantation technology coupled with the diverse
utcomes associated with a heterogeneous group of
atients limits the use of outcomes as a meaningful
ndicator for quality assessment. It is critical, in our
esire to improve measures and improve the quality of
are in transplantation, that we be cautious of ap-
roaches that use conceptually ﬂawed or inaccurate
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igure 2. The 95% conﬁdence intervals for samples drawn from a
opulation receiving a treatment that produced 50% survival.arameters or data.
44NDICATORS OF QUALITY
Quality of health care can be evaluated on the basis
f structure, process, or outcome [8]. Structural data are
argely those that describe characteristics of facilities and
roviders. Process data describe the elements of treat-
ent necessary to achieve a good outcome. Outcome
ata refer to patients’ health status after treatment. Al-
hough the outcome-reporting methods used by SRTR
annot be applied to HSCT, the situation is not hope-
ess. On the contrary, substantial progress has been
ade through efforts supported indirectly or directly
y the American Society for Blood and Marrow
ransplantation (ASBMT) and recent information
rom the IBMTR.
A study in publication from the IBMTR has done
uch to improve our understanding of the structures of
SCT programs [1]. This report describes the charac-
eristics of 163 US HSCT centers that register patients
ith the IBMTR and the Autologous Blood andMarrow
ransplant Registry. Consecutive adult patients with
eukemia receiving a matched sibling allogeneic HSCT
r those with lymphoma receiving an autologous HSCT
ere evaluated for correlations between outcome and
rovider characteristics. In this study, center factors as-
ociated with decreased mortality within 100 days after
llogeneic HSCT included a higher patients-per-physi-
ian ratio and centers where physicians answer emer-
ency calls. The afﬁliation of transplant centers with a
edical school was not associated with increased mor-
ality except when students and residents were present
ithout fellow supervision.
Caution must be exercised in interpreting these
esults, because the parameters investigated may rep-
esent surrogates for other characteristics. Because we
o not understand the relatedness of the measured
arameters to outcome, attempts to change parame-
ers to improve outcome may not succeed. For struc-
ural criteria to be meaningful, it must be demon-
trated that variations in a selected attribute result in
ifferences in outcome [8].
N = 165 centers 
31-100 
patients/year
> 100 patients/year
< 30 patients/yearFigure 3. Transplant center volume (all transplantations).
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What Is Quality in a Transplant Program?
Bccreditation
The other, and probably most important, devel-
pment for quality assessment has been voluntary ac-
reditation. The US FDA has had a growing interest
n HSCT quality, most notably through its promul-
ation of rules governing the collection, processing,
nd storage of cells and tissues [5]. However, most of
he standard-setting and compliance has been volun-
ary by the HSCT community itself.
One of the voluntary programs has been created
nd managed by the American Association of Blood
anks (AABB). It covers primarily the laboratory pro-
essing, collection, and storage phases of HSCT. Ap-
roximately 150 hematopoietic progenitor cell ser-
ices and approximately 20 umbilical cord blood banks
ave AABB accreditation. The AABB has been devel-
ping additional standards and accreditation of both
ational and international facilities. More can be learned
bout this program at http://www.aabb.org.
The other signiﬁcant and highly successful effort at
oluntary accreditation has been the formation and
rowth of the Foundation for the Accreditation of Cel-
ular Therapy (FACT). FACT came to being in 1994,
hen ASBMT developed standards for clinical pro-
rams, and the International Society for Cell Therapy
eveloped standards for laboratory programs. These
tandards were merged, published for public comment,
eviewed, and adopted as the ﬁrst edition of the FACT
tandards [9]. FACT was incorporated in 1997, and an
nspection program began in 1998 to certify programs
hat met the quality standards. The FACT standards
ddress both structural characteristics for transplant pro-
rams and processes of care. A potential criticism of
rocess measures (and programs that assess them) is that
elected measures may not be important predictors of
utcomes. As with structural measures, variations in a
elected attribute must be shown to lead to differences in
utcome to be credible. However, process data can be
ore sensitive measures of quality than outcomes data,
ecause a poor outcome does not occur every time that
here is an error in provision of care.
Although the accreditation process is only 6 years
ld, it has been widely embraced. Shortly after the
nitiation of FACT accreditation, the Joint Accredita-
ion Committee European Group for Blood and Mar-
ow Transplantation-Euro-Ishage (JACIE) was estab-
ished. Based on FACT standards, the aim of JACIE is
o create a standardized system of accreditation that is
fﬁcially recognized throughout Europe.
In addition to adopting the FACT standards (and
articipating in the revision of standards for the sec-
nd edition), JACIE has structured the inspection and
ccreditation program in Europe to be similar to the
ne in North America. The accreditation efforts of
ACT and JACIE are leading the way toward global
tandards of quality for stem cell collection, process-
R
B&MTng, and infusion. Most recently, Australia has adopted
ACT standards for collection and processing, thus
urther widening the net of quality, and other coun-
ries have similar efforts under consideration. With
he ability to transport cells and tissues internationally
or patient care, such assurances of quality are critical.
There was recognition in 2000 that the initial
ACT standards were deﬁcient with respect to the
merging area of umbilical cord blood cell processing.
o remedy this, FACT partnered with NetCord, an
nternational group of umbilical cord blood banks, to
stablish and publish joint standards for umbilical cord
lood processing [10]. FACT administers the inspec-
ion program for NetCord.
FACT standards cover all phases of collection, pro-
essing, and administration of hematopoietic progeni-
ors, and they require all collection, processing, and
linical facilities to evaluate and report clinical outcomes
nd to have a comprehensive quality-management pro-
ram in place. There are presently 128 FACT-accred-
ted programs (Table 2). Only 3 of those were found to
ave no deﬁciencies upon initial inspection. There were
03 that had minor deﬁciencies that required correction
nd a written response before accreditation was granted.
wenty programs required reinspection, thus under-
coring the rigorous nature of the accreditation process.
n accreditation must be renewed every 3 years. Fifty
enters have successfully achieved accreditation renewal.
ith respect to cord blood banks, 33 banks are regis-
ered, and 3 programs are now accredited. These results
nd the identiﬁcation of programs are all published on
he FACT Web site at http://www.factwebsite.org.
The role of center accreditation in health services
esearch has not been well studied. Accredited trauma
enters have been shown to have superior survival
utcomes, but this is confounded by the experience
nd certiﬁcations of the physicians handling the cases
11]. Although the IBMTR study [1] failed to provide
vidence that FACT accreditation leads to better sur-
ival outcomes, the study did not evaluate the role of
ccreditation in producing superior patient experience
nd satisfaction during transplantation.
tandardized Reporting and Outcomes
Transplant centers have always interacted with
ayers who have required an annual request for infor-
ation (RFI) for participation in transplant networks.
he information requested has varied widely from
able 2. Status of FACT-Accredited Facilities http://www.factwebsite.org
Status No.
egistered 224
n progress 96
ccredited 128
enewal accreditation 50
245
c
p
d
o
e
d
T
v
o
m
o
C
v
m
p
d
i
a
t
N
R
a
p
m
b
u
W
d
i
a
n
f
t
u
t
u
e
C
q
e
s
p
a
m
m
h
p
m
t
t
c
a
t
t
I
i
v
m
p
w
m
T
c
a
i
A
g
a
d
M
t
R
1
1
C. F. LeMaistre and F. R. Loberiza
2ompany to company, and the time points for reporting
osttransplantation outcomes have differed widely,
epending on the payer. Some ask for raw data, and
thers ask for percentages or actual ratios. Some pay-
rs have tried to benchmark RFI information against
atasets such as those maintained by the IBMTR.
his has been problematic, both because of the small
olume at individual centers and because of the variety
f types of transplantations and diseases. Further-
ore, the requested data often have not been parallel
r analogous to the way the IBMTR collects its data.
ompounding the earlier discussion about patient
ariables and outcomes, varied data requests only
ade the interpretations more confusing and made
ayers, as well as providers, more frustrated.
ASBMT recently undertook the responsibility of
eveloping a standardized RFI. After more than a year
n committee, a draft of the RFI was ﬁrst shared with
ll ASBMT members for their comment and was then
aken to payers for comment through the United
etwork for Organ Sharing. The ﬁnal version of the
FI was approved by the ASBMT board of directors
nd was introduced to the hematopoietic cell trans-
lantation community in January 2003. Although there
ay still be opportunity for improvement, the RFI has
een well received by all parties concerned and is now
pdated annually. The RFI is available on the ASBMT
eb site at http://www.asbmt.org, where it can be
ownloaded as an interactive ﬁle.
The types of information requested on the standard-
zed RFI include descriptive data about the transplantation
nd treatment outcome data. There are agreed-upon deﬁ-
itions of terms and how the data should be presented.The
orm differentiates adult and pediatric patients and disease
ypes. Consequently, for the ﬁrst time, we are workingwith
niform datasets. The standardized RFI has had the addi-
ional beneﬁt of getting the transplant centers out from
nder the administrative burden of responding to a differ-
nt RFI form for each payer.
ONCLUSION
In summary, we again ask the question: what is
uality in a transplant program? At present it may be
asier to deﬁne what it is not. Quality is not yet
omething that we can measure by survival statistics of
rocedures performed for individual diseases. It is not
function of volume—at least as far as we can deter-
ine [1]. Quality is not a function of the university
edical center versus the community setting. Quality,
owever, is deﬁnable and measurable for each trans-
lant program. It is achievable with a quality manage-
ent program that addresses all phases of cell collec-
ion, processing, and patient care. It is discernible
hrough standardized reporting of information, and it
an be documented by inspection to determine whether
program is meeting accepted standards.
46Members of the HSCT community can be proud of
he initiatives in quality supported by FACT, ASBMT,
he International Society for Cell Therapy, JACIE, and
BMTR. Moreover, the acceptance of quality standards,
ncluding those for clinical facilities, by the centers in-
olved in HSCT has been rapid and widespread. Ulti-
ately, however, those involved with HSCT must be
repared to deﬁne accepted outcomes. It is critical that
e ensure that the measures and outcomes we select are
eaningful to our patients, as well as to our programs.
o abdicate a leadership role in the deﬁnition of out-
omes at this juncture is to risk the acceptance of criteria
pplied by others and all the potential hazards of such
naction.
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